|
Neonatal Intensive Care Drug Manual
|
| bet | 413/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Total cumulative dose
|
|
Route
|
IM
|
Preparation
|
Do not dilute or mix with any other medications
Do not shake the vial
|
Administration
|
IM injection.
Draw up required dose and administer into anterolateral thigh. Give injection volumes >1 mL as divided doses.
|
Monitoring
|
Hypersensitivity including anaphylaxis.
|
Contraindications
|
Palivizumab is contraindicated in patients with hypersensitivity to the active substance or other humanized monoclonal antibodies. [1]
|
Precautions
|
Keep all equipment needed for the treatment of severe hypersensitivity reactions ready before the administration of palivizumab.
|
Drug interactions
|
|
Adverse reactions
|
These did not occur more commonly than in the placebo arm of a trial. [2].
Common (>1%): fever, rash, rhinitis, wheeze, cough, diarrhoea, injection site reaction, cyanosis (in children with congenital heart disease); Infrequent (0.1–1%) anaemia, elevated liver enzymes;
Rare (<0.1%) hypersensitivity (including anaphylaxis). [3]
|
Compatibility
|
Not applicable. Do not reconstitute palivizumab with any other diluents or medicinal components.
|
Incompatibility
|
Do not reconstitute palivizumab with any other diluents or medicinal components.
|
Stability
|
Administer immediately.
|
Storage
|
Refrigerate at 2O to 8 OC. Do not freeze. [1]
|
Excipients
|
Histidine and glycine and the active ingredient, palivizumab, at a concentration of 100 milligrams per mL. [1]
|
|
|
| |
